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Background
Activation of the homodimeric transmembrane guanylyl
cyclase-A (GC-A) receptor upon binding of its extracellu-
lar ligands, atrial (ANP) and B-type (BNP) natriuretic pep-
tides, leads to cyclic GMP formation in many types of
cells. This NP/GC-A pathway has a critical role in the
endocrine regulation of arterial blood pressure and vol-
ume and in the local counter-regulation of cardiac hyper-
trophy and fibrosis. Alterations of this system result in
arterial hypertension, hypervolemia and cardiac hypertro-
phy. Many studies have shown that exposure of GC-A to
high concentrations of ANP/BNP or to growth hormones
such as angiotensin II (Ang II) or endothelin provokes
homologous versus heterologous desensitization of the
receptor [1]. However, the mechanisms accounting for
this loss of function of GC-A in vivo are largely unknown.
In the present study we identified and characterized a
novel isoform of GC-A (GC-AΔLys
314-Gln 
330) with unique
structural properties. Our data reveal that this splice vari-
ant functions as dominant negative isoform and suggest
that increased alternative splicing of GC-A may contribute
to homologous or heterologous desensitization of the
NP/GC-A system.
Methods and results
Reverse transcription-PCR analyses revealed a novel iso-
form of GC-A mRNA which is expressed in all studied
murine tissues such as heart, kidney and lung, although at
a ~10-fold lower level compared to the wild-type receptor.
The isoform results from the deletion of a 51-bp sequence
in exon 4, generated by splicing a cryptic donor site to the
normal acceptor site. This alternative splicing is predicted
to delete 17 amino acids (ΔLys 
314-Gln 
330) in the mem-
brane-distal part of the extracellular ligand-binding
domain of GC-A.
The deletion is not located directly within the ligand-
binding site of GC-A (which is within the membrane-
proximal part of the extracellular domain) and therefore a
direct influence on ANP and/or BNP binding seemed
unlikely. However, molecular modeling of the extracellu-
lar domain of the splice variant indicated that subsequent
alterations in the protein structure could interfere with NP
binding or signaling. Indeed, our functional studies with
transiently transfected HEK-293 cells demonstrated that
binding of ANP and ANP-induced cyclic GMP formation
by GC-AΔLys 
314-Gln 
330 were totally abolished. Further-
more, cotransfection studies showed that this GC-A vari-
ant forms heterodimers with the wild-type receptor and
inhibits ligand-inducible cGMP generation, acting as a
dominant negative isoform.
To elucidate whether increased alternative splicing of GC-
A could participate in the negative regulation of the NP/
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GC-A system by Ang II in vivo we examined the expression
and activity of GC-A in lungs from control mice, and from
mice treated with Ang II at a dose of 300 ng/kg/min dur-
ing 7 days. Ang II – treated mice showed a markedly
enhanced pulmonary mRNA expression of spliced GC-A
which was concomitant to diminished GC-A/cGMP
responses to ANP.
Our ongoing in vitro studies are directed to investigate
whether alternative splicing of GC-A does occur in all cells
expressing the receptor, or only in specific cell types. To
address this question we use real-time RT-PCR to deter-
mine the ratio of wild-type versus spliced GC-A mRNA
expression in different primary cultured murine cells. First
results demonstrate that the splice variant is expressed in
cultured microvascular lung endothelial cells (MLEC).
Treatment of MLEC with ANP (100 nM during 7 h)
enhanced the mRNA expression of the spliced GC-A iso-
form, suggesting that alternative splicing could be
involved not only in heterologous (Ang II-induced) but
also in homologous (NP-induced) inactivation of GC-A.
Conclusion
We conclude that alternative splicing can regulate endog-
enous NP/GC-A signaling. Our observations in vivo/in
vitro indicate that Angiotensin II – and ANP-induced alter-
native splicing of GC-A may represent a novel mechanism
for reducing the sensitivity of the receptor to ANP and
BNP.
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